US EPA ARCHIVE DOCUMENT
MEMORANDUM


TO: G. LaRocca, PM#15
Registration Division (TS-769C)

FROM: Irving Mauer, Ph.D.
Geneticist, Section VI
Toxicology Branch/HED (TS-769C)

THRU: Laurence D. Chitlik, DABT
Section Head, Section V & VI
Toxicology Branch/HED (TS-769C)
and
William L. Burnam, Chief
Toxicology Branch/HED (TS-769C)

Registrant: CIEL, Brussels

Action Requested: Evaluate the following mutagenicity assay submitted by Centre International d'Etudes du Lindane (C.I.E.L.), Brussels (Monitoring Scientists: Dr. N. Wilhelm, Celamerck, D-6507 Ingelheim am Rhein):

"Mammalian Cell (V79) Mutagenicity Test on Lindane," (Report #SP 540-VT21), performed by Franz Oesch, Ph.D., Professor of Toxicology, Director, Institute of Toxicology, University of Mainz, Obere Zahlbacher StraBe 67, D-6500 Mainz.

TB Evaluation: The study is judged UNACCEPTABLE (see Data Review attached to this memo).
TOXICOLOGY BRANCH: DATA REVIEW

CHEMICAL: Lindane


CITATION: Mammalian Cell (V79) Mutagenicity Test on Lindane

ACCESSION NO./MRID NO.: 253997/NA

SPONSOR/TESTING LAB.: Centre Internation d'Etudes du Lindane (C.I.E.L.), Brussels/Franz Oesch, Ph.D., Professor of Toxicology, Director, Institute of Toxicology, University of Mainz, Obere Zahlbacher Strasse 67, D-6500 Mainz.

STUDY No./DATE: SP 540-VT21/May 28, 1984

TEST MATERIAL: Lindane technical (Batch No. 111-1), 99.8% a.i., dissolved in dimethylsulfoxide for testing.

PROCEDURES: Satisfactory as given in the attached M&M from the report, but noting the following exceptions to the agreed protocols, (6/6/83): (1) Hepatic microsomes should have been prepared from male CF-1 mice, not the reported CD-1's, since the increased tumor frequencies reported in the Thorpe & Walker study (1973) occurred in the former; (2) if the first assay is negative, a repeat experiment is required.

Results and Conclusions: Based upon data showing no increase over DMSO controls in mutant frequency (mutation to HGPRT deficiency) in either (repeated) activated or (single) non-activated cultures exposed to the test substance up to the level of toxicity and solubility, and the report states that "... lindane was completely negative in the V79 mammalian cell mutagenicity test under conditions where the positive controls clearly indicated mutagenicity."

However, as indicated above, the appropriate metabolic activation (S-9) preparation was not utilized, and hence the study is deficient in this respect.

TB EVALUATION: Unacceptable.
MAMMALIAN CELL (V79) MUTAGENICITY TEST

ON

LINDANE

Study Director: Dr. H.R. Glatt

Report No. SP 540-VT21 (13 pages)

Report Date: May 28, 1984

Sponsor Centre International d'Etude du Lindane (C.I.E.L.), Brussels
Monitoring Scientist: Dr. N. Wilhelm, Celamerck,
D-6507 Ingelheim am Rhein
Lindane toxicology review

Page _____ is not included in this copy.
Pages 4 through 7 are not included in this copy.

The material not included contains the following type of information:

- Identity of product inert ingredients
- Identity of product impurities
- Description of the product manufacturing process
- Description of product quality control procedures
- Identity of the source of product ingredients
- Sales or other commercial/financial information
- A draft product label
- The product confidential statement of formula
- Information about a pending registration action
- FIFRA registration data
- The document is a duplicate of page(s) ________
- The document is not responsive to the request

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.